Search for the latest oncology news by tumour type
Natural killers: Using the body’s cells to target breast cancer
It sounds like a plot from a Quentin Tarantino movie — something sets off natural…
Browsing: Tumour Stream
ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line immunotherapy in advanced bladder cancer
In a presentation of real-world data, researchers from Fox Chase Cancer Center, USA, have concluded…
ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations
The addition of 1 year of the PARP inhibitor olaparib after completion of standard neoadjuvant…
ASCO 2021: First AI-based tool for predicting genomic subtypes of pancreatic cancer from histology slides
The abstract and poster entitled “Identification of pancreatic adenocarcinoma molecular subtypes on histology slides using…
ASCO 2021: New insights on sarcomatoid kidney cancer
New collaborative research shows that treatment with immune checkpoint inhibitors (ICIs) has led to a…
ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a…
ASCO 2021: Targeted radiotherapy offers new treatment option for patients previously treated for metastatic castration-resistant prostate cancer
The investigational therapy 177Lu-PSMA-617 significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) when…
ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer
“Certain patients with advanced oesophageal cancer, who currently have few treatment options, now stand to…
Treatment reduces breast cancer recurrence by 42% in patients with early-stage breast cancer with an inherited BRCA1 or BRCA2 gene abnormality
Results from the OlympiA clinical trial shows that olaparib reduces breast cancer recurrence by 42%…
ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer
Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type…